Skip to content

INTENSITY THERAPEUTICS, INC.: 10-Q filed 2023-08-14

What INTENSITY THERAPEUTICS, INC. reported in its quarterly report filed 2023-08-14 (fiscal Q2 2023): 28 published measures, 79 facts as tagged in accession 0001213900-23-066740.

This filing

Form
10-Q (quarterly report)
Filed
2023-08-14
Fiscal period
fiscal Q2 2023
Accession
0001213900-23-066740 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All INTENSITY THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-06-3018,227,963USD
At 2022-12-311,757,163USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-06-303,094,445USD
At 2022-12-316,854,345USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-06-3015,133,518USD
At 2023-03-31-15,962,264USD
At 2022-12-31-15,097,182USD
At 2022-06-30-12,480,171USD
At 2022-03-31-10,776,049USD
At 2021-12-31-8,684,104USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2023-06-30135,765USD
At 2022-12-311,311,877USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-3,700,542USD91
2023-01-01 to 2023-06-30-5,037,013USD181
2022-04-01 to 2022-06-30-1,927,642USD91
2022-01-01 to 2022-06-30-4,296,689USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-01-01 to 2023-06-30-1,139,282USD181
2022-01-01 to 2022-06-30-2,816,990USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-01-01 to 2023-06-30-36,830USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-06-30-43,690,021USD
At 2022-12-31-38,653,008USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2023-04-01 to 2023-06-303,516,579shares91
2023-01-01 to 2023-06-303,463,635shares181
2022-04-01 to 2022-06-303,410,103shares91
2022-01-01 to 2022-06-303,410,103shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2023-04-01 to 2023-06-303,516,579shares91
2023-01-01 to 2023-06-303,463,635shares181
2022-04-01 to 2022-06-303,410,103shares91
2022-01-01 to 2022-06-303,410,103shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-1.05USD/shares91
2023-01-01 to 2023-06-30-1.45USD/shares181
2022-04-01 to 2022-06-30-0.57USD/shares91
2022-01-01 to 2022-06-30-1.26USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-1.05USD/shares91
2023-01-01 to 2023-06-30-1.45USD/shares181
2022-04-01 to 2022-06-30-0.57USD/shares91
2022-01-01 to 2022-06-30-1.26USD/shares181

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2023-01-01 to 2023-06-30624,253USD181
2022-01-01 to 2022-06-30500,622USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-1,221,702USD91
2023-01-01 to 2023-06-30-2,475,832USD181
2022-04-01 to 2022-06-30-1,929,796USD91
2022-01-01 to 2022-06-30-4,308,319USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-06-3018,060,225USD
At 2022-12-311,450,336USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2023-04-01 to 2023-06-30221,779USD91
2023-01-01 to 2023-06-30305,161USD181
2022-04-01 to 2022-06-3014,959USD91
2022-01-01 to 2022-06-3029,754USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-06-303,058,445USD
At 2022-12-316,818,345USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2023-06-301,581,812USD
At 2022-12-31603,176USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2023-04-01 to 2023-06-301,221,702USD91
2023-01-01 to 2023-06-302,475,832USD181
2022-04-01 to 2022-06-301,929,796USD91
2022-01-01 to 2022-06-304,308,319USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2023-04-01 to 2023-06-30859,212USD91
2023-01-01 to 2023-06-301,632,986USD181
2022-04-01 to 2022-06-301,385,966USD91
2022-01-01 to 2022-06-303,080,466USD181

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2023-06-30135,765USD
At 2022-12-311,311,877USD
At 2022-06-301,722,239USD
At 2021-12-314,539,229USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2023-06-3058,822,229USD
At 2022-12-3123,555,160USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2022-12-31139,089USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2022-12-31143,221USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2023-06-30167,738USD
At 2022-12-31167,738USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2023-06-301,476,633USD
At 2022-12-311,723,400USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2023-04-01 to 2023-06-30362,490USD91
2023-01-01 to 2023-06-30842,846USD181
2022-04-01 to 2022-06-30543,830USD91
2022-01-01 to 2022-06-301,227,853USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2023-01-01 to 2023-06-30978,636USD181
2022-01-01 to 2022-06-30290,834USD181

Inspect the source

Entity
INTENSITY THERAPEUTICS, INC. / CIK 0001567264
Captured
SEC response SHA-256
e3b01a08de9d2eb598fc1afc98358f96588cb7c0f58146200ed65e229957262a

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001567264.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))